You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Fixed-effects results of NMA comparing tedizolid with each of the seven comparator drugs (odds ratios [95% credible intervals])

From: Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA

Outcome Comparator Drug
Ceftaroline Daptomycin Linezolid Teicoplanin Telavancin Tigecycline Vancomycin
Clinical response at the end of treatment
 All trials 0.7 [0.0, 30.6] NA 1.0 [0.7, 1.3] 2.2 [0.6, 9.0] NA NA 1.7 [1.0, 3.0]
 ITT/mITT only NA NA 1.0 [0.7, 1.3] 2.2 [0.6, 9.0] NA NA 1.5 [0.8, 2.6]
Clinical response at PTE/TOC
 All trials 1.0 [0.3, 3.5] 1.4 [0.5, 3.8] 1.0 [0.7, 1.4] NA 1.4 [0.9, 2.3] 3.2 [0.8, 16.9] 1.6 [1.1, 2.5]
 ITT/mITT only 1.0 [0.3, 3.5] 1.4 [0.5, 3.8] 1.0 [0.7, 1.4] NA 1.4 [0.9, 2.3] 3.2 [0.8, 16.7] 1.6 [1.1, 2.5]
 MRSA only NA 2.1 [0.4, 13.4] 1.0 [0.4, 2.3] NA 1.1 [0.4, 3.0] 3.2 [0.7, 20.0] 1.6 [0.7, 4.0]
Post hoc sensitivity analysis
 MRSA only 1.2 [0.4, 3.6] 2.1 [0.4, 13.5] 1.0 [0.4, 2.3] NA 1.1 [0.4, 3.0] 3.2 [0.7, 20.0] 1.6 [0.7, 4.0]
Discontinuation due to AE
 All trials 0.3 [0.0, 7.1] 0.8 [0.0, 45.8] 0.5 [0.1, 1.9] NA 0.3 [0.1, 1.3] NA 0.4 [0.1, 1.8]
  1. Bold text indicates CrI that do not cross 1 and favour tedizolid
  2. AE adverse event, CRI credible intervals, EOT end of treatment, ITT intention to treat, mITT modified intention to treat, MRSA methicillin-resistant Staphylococcus aureus, NA not available, PTE post-treatment evaluation, TOC test of cure